Jozef Vermylen

Jozef Vermylen's AcademicInfluence.com Rankings

Jozef Vermylen

Medical

#2213

World Rank

#2619

Historical Rank

Cardiology

#196

World Rank

#201

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Jozef Vermylen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jozef Vermylen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. (2004) (419)
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. (1995) (343)
Ultrafine particles affect experimental thrombosis in an in vivo hamster model. (2002) (329)
“Lupus” Anticoagulant and Thrombosis – Possible Role of Inhibition of Prostacyclin Formation (1982) (326)
THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS (1985) (302)
Diesel Exhaust Particles in Lung Acutely Enhance Experimental Peripheral Thrombosis (2003) (296)
Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties. (1992) (243)
Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. (2001) (226)
Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. (2003) (217)
Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. (1994) (185)
Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. (1993) (167)
Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. (1998) (166)
A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. (1982) (163)
Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII Concentrate (1997) (158)
PROLONGING PROSTACYCLIN PRODUCTION BY NAFAZATROM OR DIPYRIDAMOLE (1984) (156)
Dipyridamole Inhibits Platelet Aggregation in Whole Blood (1983) (145)
Physico-chemical and proenzyme properties of NH2-terminal glutamic acid and NH2-terminal lysine human plasminogen. Influence of 6-aminohexanoic acid. (1974) (135)
EXCESSIVE CONSUMPTION OF BLOOD COAGULATION COMPONENTS AS CAUSE OF HEMORRHAGIC DIATHESIS. (1965) (130)
Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. (1987) (125)
Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. (1991) (123)
A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. (2000) (122)
Mechanism of the Antiplatelet Action of Dipyridamole in Whole Blood: Modulation of Adenosine Concentration and Activity (1986) (117)
Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and Inhibitor (1999) (116)
Catheter-directed lysis of iliofemoral vein thrombosis with use of rt-PA (1997) (110)
Thrombolytic Therapy with Streptokinase Using a Standard Dosage Scheme (1966) (110)
Outcome of Recent Thromboembolic Occlusions of Limb Arteries Treated with Streptokinase (1970) (108)
Lack of Platelet Response to Collagen Associated with an Autoantibody against Glycoprotein Ia: A Novel Cause of Acquired Qualitative Platelet Dysfunction (1989) (103)
von Willebrand factor binds to native collagen VI primarily via its A1 domain. (1997) (101)
Hepatitis C virus‐RNAs in plasma and in peripheral blood mononuclear cells of hemophiliacs with chronic hepatitis C: Evidence for viral replication in peripheral blood mononuclear cells (1994) (99)
Questions and Answers on Prothrombin Time Standardisation in Oral Anticoagulant Control (1985) (97)
Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. (1984) (97)
A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. (2000) (94)
Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. (1999) (92)
Intravascular coagulation in liver disease. (1974) (90)
The platelet insulin receptor: detection, partial characterization, and search for a function. (1988) (89)
Characterization of N,N’-bis(3-Picolyl)-4-Methoxy-Isophtalamide (Picotamide) as a Dual Thromboxane Synthase Inhibitor/Thromboxane A2 Receptor Antagonist in Human Platelets (1989) (86)
Renal artery stent placement with use of the Wallstent endoprosthesis. (1991) (85)
Thrombosis and immune disorders. (1986) (85)
The effect of streptokinase infusion on chronic arterial occlusions and stenoses. (1971) (82)
Role of platelet activation and fibrin formation in thrombogenesis. (1986) (80)
von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen (2006) (78)
Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. (1996) (78)
Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. (1995) (74)
Dietary cholesterol withdrawal reduces vascular inflammation and induces coronary plaque stabilization in miniature pigs. (2002) (73)
Turnover of fibrinogen, plasminogen, and prothrombin during exercise in man. (1977) (71)
Aggregation of Human Platelets by Bovine or Human Factor VIII: Role of Carbohydrate Side Chains (1973) (68)
Retraction of reptilase-clots in the presence of agents inducing or inhibiting the platelet adhesion-aggregation reaction (1973) (67)
Familial Bleeding Tendency with Partial Platelet Thromboxane Synthetase Deficiency: Reorientation of Cyclic Endoperoxide Metabolism (1981) (65)
Factor VIII inhibitors (1993) (64)
Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. (2000) (64)
Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. (1995) (63)
Decreased vascular prostacyclin (PGI2) in diabetic rats. Stimulation of PGI2 release in normal and diabetic rats by the antithrombotic compound Bay g 6575. (1980) (63)
Disturbed platelet aggregation to collagen associated with an antibody against an 85- to 90-Kd platelet glycoprotein in a patient with prolonged bleeding time. (1991) (60)
A Double Blind Study of the Effect of Tranexamic Acid in Essential Menorrhagia (1968) (60)
CONGENITAL MACROTHROMBOCYTOPENIA, LEUCOCYTE INCLUSIONS, DEAFNESS AND PROTEINURIA: FUNCTIONAL AND ELECTR0NMICROSCOPIC OBSERVATIONS ON PLATELETS AND MEGAKARYOCYTES (1988) (59)
A plasma factor in uraemia which stimulates prostacyclin release from cultured endothelial cells. (1980) (58)
Leukotriene B4 production by stimulated whole blood: comparative studies with isolated polymorphonuclear cells. (1986) (56)
The platelet ATP and ADP receptors. (2006) (56)
Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters. (1995) (54)
Congenital disorders of glycosylation type Ia and IIa are associated with different primary haemostatic complications (2001) (53)
Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study. (1988) (51)
Platelet activation. (1995) (51)
Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism. (1985) (50)
Continuous Quantitative Monitoring of Mural, Platelet-Dependent, Thrombus Kinetics in the Crushed Rat Femoral Vein (1991) (50)
Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody (2006) (50)
Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. (1993) (50)
Thromboxane Synthase Inhibition Combined with Thromboxane Receptor Blockade: A Step Forward in Antithrombotic Strategy? (1984) (49)
PLASMA 6-KETO-PGF1α LEVELS AFTER PLASMA EXCHANGE IN THROMBOTIC THROMBOCYTOPENIC PURPURA (1980) (45)
Are antiphospholipid antibodies clinically relevant in dialysis patients? (1992) (44)
Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom. (1983) (44)
An echistatin‐like Arg‐Gly‐Asp (RGD)‐containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function (1994) (44)
Normal mechanisms of platelet function. (1983) (44)
Platelet Aggregation by a Specific Human Immunoglobulin Preparation (1970) (43)
Evidence that bovine factor VIII, not bovine fibrinogen, aggregates human platelets (1973) (42)
High Titer Inhibitors in Severe Haemophilia A (1994) (41)
Hematologic aspects of end-stage renal failure (1994) (40)
Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin. (1995) (39)
The role of the fibrinolytic system in thromboembolism. (1979) (39)
Human platelet aggregation by murine monoclonal antiplatelet antibodies is subtype-dependent. (1993) (39)
Percutaneous transluminal renal angioplasty: Initial results and long-term follow-up in 202 patients (1990) (39)
R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin (1990) (37)
Antihypertensive Action and Serotonin‐Induced Platelet Aggregation During Long‐Term Ketanserin Treatment in Hypertensive Patients (1984) (37)
Heparin-Induced Thrombocytopenia Platelet Aggregation Studies in the Presence of Heparin Fractions or Semi-Synthetic Analogues of Various Molecular Weights and Anticoagulant Activities (1986) (37)
Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha‐2b interferon is not a predictor for sustained response to treatment (1994) (35)
Feasibility of Adequate Thrombolytic Therapy with Streptokinase in Peripheral Arterial Occlusions: I. Clinical and Arteriographic Results (1963) (34)
Abnormal prostacyclin metabolism in the hemolytic uremic syndrome: equivocal effect of prostacyclin infusions. (1982) (34)
Effects of thromboxane A2 on lymphocyte proliferation. (1985) (33)
Protective Effect of Vitamin E on Immune Triggered, Granulocyte Mediated Endothelial Injury (1984) (32)
Platelet‐Aggregating Activity in Neuraminidase‐Treated Human Cryoprecipitates: Its Correlation with Factor‐VIII‐Related Antigen (1974) (31)
EFFECTIVENESS AND TOLERABILITY OF CV-3988, A SELECTIVE PAF ANTAGONIST, AFTER INTRAVENOUS ADMINISTRATION TO MAN (1988) (31)
Sodium fluoride mimics effects of both agonists and antagonists on intact human platelets by simultaneous modulation of phospholipase C and adenylate cyclase activity (1987) (30)
The identification of fibrinogen derivatives in plasma and serum by agarose gel filtration. (2009) (30)
Influence of Anticoagulation on Blood Loss Following Dental Extractions (1992) (30)
Fatal complication of desmopressin (1995) (29)
Dental extractions in hemophilia: reflections on 10 years' experience. (1985) (29)
Biochemical Changes Noted during Intermittent Administration of Streptokinase (1978) (28)
Wound Healing Following Dental Extractions in Rabbits: Effects of Tranexamic Acid, Warfarin Anti-coagulation, and Socket Packing (1984) (28)
Immunoglobulin G antibodies to lymphadenopathy-associated virus in differently treated French and Belgian hemophiliacs. (1985) (27)
Recurrent arterial thrombosis linked to autoimmune antibodies enhancing von Willebrand factor binding to platelets and inducing Fc gamma RII receptor-mediated platelet activation. (1998) (27)
Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations. (1983) (27)
Enkephalins Modify Granulocyte-Endothelial Interactions by Stimulating Prostacyclin Production (1983) (26)
CLOTTING AND FIBRINOLYTIC ACTIVITIES IN PERITONEAL FLUID (1981) (25)
Production and nucleotide sequence of an inhibitory human IgM autoantibody directed against platelet glycoprotein Ia/IIa. (1994) (25)
Percutaneous transluminal angioplasty of the subclavian artery: Early and late results (2007) (25)
Enhancing the Fibrinolytic Activity in Human Blood by Occlusion of Blood Vessels (1962) (24)
High obstruction of urine flow as a complication of the treatment with fibrinolysis inhibitors of haematuria in haemophiliacs. (1968) (24)
Partial isolation and function of the prostacyclin regulating plasma factor. (1985) (24)
PLATELET AND VASCULAR ARACHIDONIC ACID METABOLITES: CAN THEY HELP DETECT A TENDENCY TOWARDS THROMBOSIS? * (1984) (24)
Evidence that Washed Human Platelets Possess Factor‐X Activator Activity (1977) (23)
Fluorescent chemical cleavage of mismatches for efficient screening of the factor VIII gene (1998) (23)
Fast and Reproducible Vascular Neointima Formation in the Hamster Carotid Artery: Effects of Trapidil and Captopril (1995) (23)
PROSTACYCLIN AND PRE-ECLAMPSIA (1981) (23)
Evidence that ‘Activated’ Prothrombin Concentrates Enhance Platelet Coagulant Activity (1978) (22)
Immunological Alterations in Haemophiliacs Treated with Lyophilized Factor VIII Cryoprecipitate from Volunteer Donors (1984) (22)
Thrombolytic therapy with streptokinase using a standard dosage. (1966) (22)
Air pollution and thrombosis: an experimental approach (2002) (22)
Metabolism and distribution of fibrinogen. II. Fibrinogen turnover in polycythaemia, thrombocytosis, haemophilia A, congenital afibrinogenaemia and during streptokinase therapy. (1972) (22)
The Effect of Clinical Prostacyclin Infusions in Advanced Arterial Disease on Platelet Function and Plasma 6‐keto PGF1α Levels (1981) (22)
A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains. (1993) (21)
ADP receptors in platelet activation and aggregation. (2000) (21)
Peripheral arterial diseases. (1981) (20)
Blood loss following dental extractions in anticoagulated rabbits: effects of tranexamic acid and socket packing. (1985) (20)
Double blind evaluation of the haemostatic effect of adrenochrome monosemicarbazone, conjugated oestrogens and epsilonaminocaproic acid after adenotonsillectomy. (1968) (19)
Platelet fatty acids and function in two distinct regions of Belgium: relationship to age and dietary habits (1991) (19)
Platelet hypersensitivity to serotonin after prolonged ketanserin intake? (1985) (19)
Sodium Acetate Buffer (1975) (19)
Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. (1985) (19)
Guanine nucleotide-dependent inhibition of phospholipase C in human endothelial cells. (1990) (18)
Evidence that Endotoxins Enhance the Factor X Activator Activity of Washed Human Platelets (1978) (18)
The feasibility of adequate thrombolytic therapy with streptokinase in peripheral arterial occlusions (1962) (18)
Measurement of von Willebrand factor antigen in plasma and platelets with an enzyme-linked immunosorbent assay based on two murine monoclonal antibodies. (1991) (18)
Reversible deficient prostacyclin release in childhood hemolytic uremic syndrome. (1982) (18)
Ridogrel, a Combined Thromboxane Synthase Inhibitor and Receptor Blocker, Decreases Elevated Plasma β-Thromboglobulin Levels in Patients with Documented Peripheral Arterial Disease (1990) (18)
Factor VIII and Human Platelet Aggregation (1976) (18)
Is the Apparent Outbreak of Hepatitis A in Belgian Hemophiliacs due to a Loss of Previous Passive Immunity? (1994) (18)
The Streptokinase Reactivity Test. I. Standardization (1963) (18)
Hepatitis G Viral RNA in Serum and in Peripheral Blood Mononuclear Cells and Its Relation to HCV-RNA in Patients with Clotting Disorders (1997) (17)
Effect of furosemide on plasma fibrinolytic activity and urokinase excretion. (1977) (17)
Lumbar artery pseudoaneurysm and arteriovenous fistula as a complication of laparoscopic splenectomy: treatment by transcatheter embolization (2002) (17)
Inhibition of human platelet aggregation by plasmin digests of human and bovine fibrinogen preparations: role of contaminating factor VIII-related material. (1974) (17)
[Platelet aggregation by Thrombofax]. (1972) (16)
R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. (1990) (16)
Indomethacin and Platelet Aggregation in Chronic Glomerulonephritis: Existence of Non-responders (1974) (16)
[Expert consensus document on the use of antiplatelet agents]. (2004) (16)
Biological Effects of the Administration of an Equimolar Streptokinase-Plasminogen Complex in Man (1977) (15)
Dissociation of Clot Retraction from Platelet Granule Fusion and Degranulation: an Ultrastructural Study of Reptilase—Human Platelet‐rich Plasma Clots (1975) (15)
Some effects of indomethacin on platelet function, blood coagulation and fibrinolysis. (1971) (15)
Metabolism of iodine-labeled plasminogen during streptokinase and reptilase therapy in man☆☆☆ (1973) (15)
Complement-Dependent and Complement-Independent Interactions of Bacterial Lipopolysaccharides and Mucopeptides with Rabbit and Human Platelets (1979) (15)
Inhibitory Effect of Piracetam on Platelet-rich Thrombus Formation in an Animal Model (1998) (15)
Parvovirus B19 Antibodies in Patients with Haemophilia A (1995) (15)
Platelets and thrombosis (1973) (14)
αIIbβ3 antagonism vs. antiadhesive treatment to prevent platelet interactions with vascular subendothelium (2004) (14)
COMBINING ANTIPLATELET AGENTS: POTENTIATION BETWEEN ASPIRIN AND DIPYRIDAMOLE (1985) (14)
A monoclonal antibody directed against human von Willebrand factor induces type 2B‐like alterations (2004) (14)
Prolonged Inhibition of Acute Arterial Thrombosis by High Dosing of a Monoclonal Anti-platelet Glycoprotein IIb/IIIa Antibody in a Baboon Model (1995) (14)
"LUPUS" ANTICOAGULANT AND PROSTACYCLIN (1981) (14)
L-652,343, a novel dual cyclo/lipoxygenase inhibitor, inhibits LTB4-production by stimulated human polymorphonuclear cells but not by stimulated human whole blood. (1987) (14)
Absence of Potentiation with Murine Antiplatelet GPIIb/IIIa Antibody of Thrombolysis with Recombinant Tissue-Type Plasminogen Activator (rt-PA) in a Canine Venous Thrombosis Model (1989) (14)
The Molecular Basis of Antithrombin Deficiency in Belgian and Dutch Families (1998) (13)
BM 13.177 selectively inhibits endoperoxide analogue induced vascular contractions. (1985) (13)
Autotransfusion during aorto-iliac surgery. (1990) (13)
Hepatitis C virus genotypes in belgian hemophiliacs (1995) (13)
Arterial occlusion and thrombus aspiration after total knee arthroplasty. (1999) (13)
Congenital deficiency of the phospholipase C coupled P2Y1 receptor leads to a mild bleeding disorder. (1999) (13)
ENZYMATIC CLOT DISSOLUTION IN MAN: A NEW THERAPEUTIC APPROACH. (1964) (12)
Comparison between the Changes in the Plasma Fibrinogen and Plasminogen Levels Induced by a Moderate or High Initial Dose of Streptokinase (1970) (12)
Inhibition of human platelet aggregation by plasmin digests of human factor VIII. (1973) (12)
Inhibition of Clot Retraction by Previous In Vitro Platelet Aggregation (1971) (12)
Epidemic of factor VIII inhibitors linked to factor VIII-P. (1991) (12)
Factor VIII and Human Platelet Aggregation (1976) (12)
Effect of platelets on clot structuration. A thrombelastographic study (1973) (12)
TTV infection and its relation to serum transaminases in apparently healthy blood donors and in patients with clotting disorders who have been investigated previously for hepatitis C virus and GBV‐C/HGV infection in Belgium (2002) (12)
Fibrinogen ‘Leuven’, Another Genetic Variant (1974) (11)
Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man. (1996) (11)
Molecular Size Distribution of Fibrinogen Derivatives Formed in Vitro and in Vivo: a Chromatographic Study (1976) (11)
Hirudo medicinalis and hirudin (1991) (11)
Indomethacin treatment of membranoproliferative and lobular glomerulonephritis. (1973) (11)
Platelet factor 3--properties and clinical significance. (1972) (11)
Factor VIII and Human Platelet Aggregation (1976) (11)
Campylobacter fetus subspecies fetus infection of an abdominal aneurysm. (1989) (10)
Low prostacyclin synthetase activity of fetal rat aorta. Progressive increase after birth. (1983) (10)
Bay g 6575, An Anti Thrombotic Compound that Stimulates Prostacyclin Release from the Vessel Wall (1979) (10)
Anti-hepatitis G E2 Antibody Detection and Its Relation to Serum HGV-RNA in Patients with Clotting Disorders: High Prevalence of HGV Infection and Spontaneous Remission (1998) (10)
Short-term morphologic results of percutaneous transluminal renal angioplasty as determined with angiography. (1989) (10)
Acute effect of cigarette smoking on cardiac prostaglandin synthesis and platelet behavior in patients with coronary heart disease. (1983) (10)
Synergistic Antiplatelet Effect of Ridogrel, a Combined Thromboxane Receptor Antagonist and Thromboxane Synthase Inhibitor, and UDCG-212, a cAMP-Phosphodiesterase Inhibitor (1993) (10)
Blood Changes and Enhanced Thromboxane and 6-Keto Prostaglandin F1α Production in Experimental Acute Plasmodium Bergei Infection in Hamsters (1984) (10)
Diagnostic significance of antinuclear antibodies in neurologic patients (1991) (10)
Alpha 1 antagonistic and antiserotoninergic action during administration of ketanserin. (1983) (10)
Possible role of platelet activation in the pathogenesis of the transient neonatal hyperammonemia syndrome (1991) (10)
Reversible hypoprothrombinemia in a patient with primary biliary cirrhosis treated with rifampicin. (1995) (10)
Fc-independent cross-linking of a novel platelet membrane protein by a monoclonal antibody causes platelet activation. (1994) (10)
EFFICACY OF THROMBOLYTIC THERAPY WITH STREPTOKINASE USING A NEW ADMINISTRATION SCHEME. (1964) (10)
Increased release of vascular prostacyclin-like activity after long-term treatment of diabetic rats with Bay g 6575. (1981) (10)
10 Acquired disorders of platelet function (1989) (9)
Prostacyclin production by whole blood from children: impairment in the hemolytic uremic syndrome and excessive formation in chronic renal failure. (1983) (9)
Grey platelet syndrome: evidence for alpha-granule localization of the platelet plasminogen activator inhibitor-1 pool. (1991) (9)
Action of Brinase on Human Fibrinogen and Plasminogen (1979) (9)
Hepatitis G viral RNA in serum and in peripheral blood mononuclear cells and its relation to HCV-RNA in patients with clotting disorders. (1997) (9)
Indomethacin and urinary excretion of fibrinogen-like material in proliferative glomerulonephritis. (1970) (9)
Acute and Chronic “Defibrination” in Obstetrical Practice (1968) (9)
Direct quantitation of oxidized low-density-lipoprotein (oxldl) and assessment of its pole in atherothrombosis in end-stage renal-disease (esrd) patients (1995) (9)
Immunization of haemophiliacs against hepatitis B. A joint study between the haemophilia centers in Leuven, Belgium and Malmö, Sweden. (2009) (9)
Evidence that Human Platelet Aggregating Activity in Porcine Plasma is a Property of von Willebrand Factor (1974) (8)
Intraarterial low-dose streptokinase infusion in the treatment of acute renal thromboembolism. (1987) (8)
Intravenous ionic contrast media cause local prostacyclin release in man. (1985) (8)
Characterisation of a Novel Series of Aprotinin-derived Anticoagulants (1995) (8)
Thromboxane A2 and prostacyclin do not modulate the systemic hemodynamic response to cold in humans. (1985) (8)
Furosemide: its role on certain platelet functions. (1977) (7)
PLATELET INHIBITORY ACTIVITY OF PROSTACYCLIN IN THE PRESENCE OF ERYTHROCYTES AS STUDIED WITH THE IMPEDANCE AGGREGOMETER (1984) (7)
The antiphospholipid syndrome and pregnancy (1995) (7)
Fibrinogen degradation products and a fibrinogen assay based on clotting kinetics. (2009) (7)
The Tanned Red Cell Hemagglutination Inhibition Immunoassay and purified fibrinogen degradation products. (2009) (7)
Dose-responses to inducers and inhibitors of platelet aggregation analysed via a micro-method. (1996) (7)
A Simple Indirect Method to Evaluate Platelet (1973) (6)
Effect of Aspirin on the Thrombelastogram of Human Blood (1973) (6)
In vitro and in vivo Recovery of Cryoprecipitated Factor VIII (1970) (6)
Human platelet aggregation by murine monoclonal antibodies is subtype-dependent (1993) (6)
The prostacyclin stimulating plasma factor (pspf) protects endothelial-cells from exhaustion (1983) (6)
Dual Regulation of Phospolipase C Activity by G Proteins (1993) (6)
A simple method to study the "stabilising" effect of chemicals and drugs on the platelet membrane (1972) (6)
Prostacyclin (pgi2) production by aortic rings and mesometrial triangles in pregnant rats, fed an anti-vitamin-e stress diet (1983) (6)
Production and nucleotide-sequence of an inhibitory human-igm autoantibody directed against platelet glycoprotein-ia (1993) (6)
Protein requirement for platelet aggregation. (2009) (6)
Selective embolization of a superior gluteal artery pseudoaneurysm associated with von Willebrand's disease. (1996) (6)
Endogenous antiaggregatory prostaglandins can contribute to inhibition of hemostasis: a pharmacological study in vivo in humans. (1987) (6)
Loss of Gs activity in platelets from carriers with a heterozygous missense mutation in the regulator of G-protein signaling 2 (RGS2) (2008) (6)
The staphylococcal clumping test for detection of fibrinogen-like material. (2009) (6)
Influence of chlorpropamide and glucose on fibrinolytic activity. (1963) (6)
R68070, a combined thromboxane synthase (tsi) and receptor blocker (tra), reduces thrombus formation in rats (1989) (6)
Detection of fibrinogen antigens with two latex techniques applied to urine concentrates (1973) (6)
Platelet factor-4--methods of study. (1972) (6)
Hepatitis B vaccination of hemophiliacs. (1983) (6)
Continuous inhibition of serotonin-induced platelet aggregation during chronic ketanserin administration to man can be detected after plasma pH control. (1987) (5)
Dissociation between platelet factor 3 availability and platelet aggregation. (2009) (5)
The P2Y1 Receptor Antagonist Adenosine-2’,5’-Diphosphate Non-selectively Antagonizes the Platelet P2X1 Ion Channel (2001) (5)
Human platelet aggregation by Thrombofax. An electron-microscopic study of the sequence of events. (2009) (5)
G4120, a rgd-containing cyclic pentapeptide, prevents neointima formation in injured hamster carotid arteries (1993) (5)
EFFECT OF DYDROGESTERONE (DUPHASTON) ON HAEMOSTASIS AND LIVER FUNCTION (1973) (5)
Factor VIII inhibitors in previously treated haemophilia A patients after treatment with a double-virus inactivated plasma-derived factor VIII concentrate (Bisinact) (1995) (5)
More on: uncertain times for research on hemophilia and allied disorders (2005) (5)
Responder-nonresponder behavior of human-platelets towards thromboxane synthase inhibitors (tsi) is due to difference in adenylate-cyclase sensitivity (1985) (5)
Comparison of Quantification Methods of111In-Labelled Platelet Deposition in Peripheral Bypass Grafts (1987) (5)
Practical Method for Thrombolytic Therapy With Streptokinase (1964) (5)
Urinary excretion of fibrinogen-fibrin-related antigen in glomerulonephritis: effect of indomethacin. (1973) (5)
Thrombosis as an immune phenomenon (1987) (5)
Thrombosis in particular organ veins. (1989) (5)
Diesel exhaust particles deposited in the lung enhance thrombus formation in peripheral vessels in an in vivo model of vascular thrombosis (2003) (5)
Factor VIII and Human Platelet Aggregation (1976) (5)
Measurement of urinary fibrinogen-related material: methodologic aspects. (1974) (5)
Blood changes and enhanced thromboxane-b2 and 6-keto prostaglandin production in acute plasmodium-bergei infection in hamsters (1983) (5)
Fc-independent cross-linking of a novel platelet membrane protein by a monoclonal antibody causes platelet activation (1994) (4)
The effect of sulphinpyrazone on whole blood thromboxane and prostacyclin generation in man. (1982) (4)
Pai-1 is not synthesized in human platelets (1991) (4)
ENHANCING BLOOD FIBRINOLYTIC ACTIVITY BY A NIACIN COMPOUND ACTIVATION AND NONACTIVATION (1965) (4)
Relaxation of retracted clots: a thrombelastographic study. (1974) (4)
Response to DDAVP in mild/moderate haemophilia A patients according to the underlying Factor VIII genotype (2003) (4)
Platelet factor 3--methods of study. (1972) (4)
Mouse carotid artery ligation induces platelet-leukocyte dependent luminal fibrin, required for neointima formation (2001) (4)
Functional polymorphisms in the paternally expressed XLαs and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation resulting in platelet Gs hyperfunction (2003) (4)
Intra-arterial injection of papaverine in the decision of balloon dilatation of the iliac arteries. (1989) (4)
Significance of urinary excretion of fibrin degradation products during treatment of glomerulonephritis. (1976) (4)
Platelet factor-4--properties and clinical significance. (1972) (4)
Human platelet clumping by bovine fibrinogen. (1972) (4)
Anti-vWf antibodies induce GPIbalpha and FcgammaRII mediated platelet aggregation only at low shear forces. (2001) (4)
Clinical ineffectiveness of intra-arterial or intra-venous infusions of epoprostenol in patients with peripheral obliterative disease, Stage III to IV (1984) (4)
Point mutations scattered in the FVIII C1 and C2 domains reduce FVIII binding to vWF and are associated to mild/moderate hemophilia A (1999) (4)
Antithrombotic potential of low-dose aspirin. (1984) (3)
The Effect of Endotoxins on Generation of Thrombin in the Platelet Atmosphere (1975) (3)
A patient with mild hemophilia A and a high titer antifactor VIII antibody against exogenous factor VIII only: clinical features, surgical management, and partial characterization of the inhibitor (1997) (3)
Dissimilar effect of two anti-anginal drugs belonging to the benzofuran group on the action of coumarin derivatives. (1968) (3)
Local low-dose thrombolysis in arterial disease of the limbs. (1987) (3)
Platelet-endotoxin interaction: a review. (1976) (3)
Lack of synergism between dazoxiben and dipyridamole following administration to man. (1985) (3)
A Sudden Outbreak of Inhibitors During Treatment With a Particular Pasteurized Factor-viii Concentrate (fviii-cps-p) - Characterization of Specific Antibodies (1993) (3)
In vitro and in vivo evaluation of two factor VIII concentrates virally inactivated by solvent-detergent or by pasteurization. (1991) (3)
Molecular mechanis of mild/moderate hemophilia A: substitution ILE2098SER in the Factor FVIII (FVIII) C1 domain impairs FVIII binding to von Willebrand factor without altering FVIII production (1999) (3)
Feasibility of Adequate Thrombolytic Therapy with Streptokinase in Peripheral Arterial Occlusions: II. Changes in Peripheral Blood and Thrombolysis in vivo* (1963) (3)
Human platelet clumping by bovine fibrinogen during its degradation. (2009) (3)
Deletion of residue Ala2201 in the Factor VIII C2 domain results in mild haemophilia A and destroys a major antigenic determinant recognized by Factor VIII inhibitor antibodies (2001) (3)
Plasma from Patients with Hepatic or Renal Failure Stimulates Prostacyclin Release from “Exhausted” Rat Aorta Slices (1979) (3)
Drugs affecting blood coagulation and hemostasis (1986) (3)
A VITAMIN K ANTAGONIST RAPIDLY REVERSES A BLUE TOE SYNDROME IN A PATIENT WITH LUPUS ANTICOAGULANT AND ANTIPROTHROMBIN ANTIBODIES (2002) (3)
Manipulation of the local thromboxane and prostacyclin balance invivo by anti-thrombotic compounds (1983) (3)
A murine monoclonal-antibody against platelet glycoprotein iib iiia potently inhibits platelet functioning invitro and invivo (1991) (3)
Pharmacological manipulation of the thromboxane pathway in blood platelets. (1990) (3)
Fibrinogen degradation in vivo: effect on the Reptilase time and on the thrombin time. (2009) (3)
On the role of guanine nucleotide binding regulatory proteins (G-proteins) in signal transduction in human platelets: studies with sodium fluoride (NaF). (1986) (3)
The clinical value of duplex surveillance following internal carotid artery reconstruction. (1997) (3)
Epinephrine induces a late thromboxane-dependent platelet shape change and enhances synergistically the shape change induced by other platelet agonists. (1995) (3)
Letters to the EditorF.D.P. (1972) (2)
ADP-induced activation of the extracellular-regulated kinase/mitogen-activated protein kinase pathway via the ionotropic P2X1 receptor in platelets. (2000) (2)
The antigenic determinant of fibrin(ogen) measured with agglutination inhibition immunoassays (1974) (2)
Clinical pharmacology of anti-aggregating substances. (1975) (2)
Dipyridamole inhibits platelet-aggregation in whole-blood invitro and exvivo (1983) (2)
Hypofibrinogenemia in histiocytosis X, type Letterer-Siwe disease. (1973) (2)
Commercially available intravenous immunoglobulins (iv igs) inhibit binding of anti-glycoprotein (gp)iib-iiia antibodies to their antigens in chronic idiopathic thrombocytopenic purpura (itp) patients (1991) (2)
A murine monoclonal-antibody against vonwillebrand-factor (vwf) increases vwf binding to human platelet glycoprotein (gp) ib and gp iib/iiia (1991) (2)
Laboratory and clinical evaluation of concentrates for treatment of haemophilia. (1975) (2)
Venous thromboses in particular organs. (1986) (2)
Antigen-antibody complexes made of FVIII and autologous specific antidbodies down- regulate the production of anti-Factor VIII antibodies (1994) (2)
Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products. (1993) (2)
PRACTICAL METHOD FOR THROMBOLYTIC THERAPY WITH STREPTOKINASE. MAINTENANCE OF NEARLY COMPLETE PLASMINOGEN DEPLETION ASSOCIATED WITH HIGH CIRCULATING ACTIVATOR ACTIVITY. (1964) (2)
Influence of the prostacyclin regulating plasma factor on human vascular endothelium in a microcirculation model (1985) (2)
Human platelet activation-induced by antibody-mediated cross-linking of a novel platelet receptor (1993) (2)
The Induction of Platelet Aggregates in Healthy Subjects by Venousocclusion (1977) (2)
Clinical trial of Brinase and anticoagulants as a method of treatment for advanced limb ischemia (2004) (2)
Synergistic effect of udcg212, a phosphodiesterase inhibitor (pde-i), and r68070, a combined thromboxane receptor antagonist (tra) and thromboxane synthase inhibitor (tsi), on platelet camp levels (1989) (2)
Genetic and acquired risk factors of venous thromboembolism (2004) (2)
Clinical and laboratory experience with fraction R: attempts at identifying the active principle (1977) (2)
[The lupus inhibitor]. (1981) (2)
Comparison of the Tanned Red Cell Hemagglutination Inhibition Immuno-assay and radial immunodiffusion for the quantitation of fibrinogen-related antigen in urine concentrates. (2009) (2)
Local thrombolysis in femoropopliteal occlusion: Early and late results (2007) (2)
Antithrombotic Potential of Thromboxane Synthase Inhibitors: Problems and Possible Solutions (1985) (2)
In vivo production of functional anti-factor VIII antibodies in severe combined immunodeficiency (SCID) mice reconstituted with PBL of healthy blood donors (1997) (2)
von Willebrand factor-dependent protection of factor VIII from inactivation by inhibitor antibody: study with a human monoclonal antibody (2000) (2)
Sodium fluoride mimics effects of both agonists and antagonists on intact human platelets by simultaneous modulation of phospholipase C and adenylate cyclase activity. (1987) (2)
In Vitro And In Vivo Effects Of An Inhibitor Of Thromboxane Synthetase (1981) (2)
[Platelet membrane changes and aggregation]. (1969) (2)
Mutation Arg2150His in the factor VIII C1 domain alters the binding of factor VIII to von Willebrand factor and is responsible for a mild hemophilia phenotype (1998) (2)
KEEPING ARTERIOVENOUS SHUNTS PATENT (1967) (2)
collagen, prevents platelet-rich thrombosis in hamsters Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to (2011) (1)
Auto-antibodies induce von Willebrand factor mediated platelet activation via immune complex formation in a patient with recurrent thrombosis (1997) (1)
Increased release of prostacyclin-like activity from rat aorta by plasma from patients with hepatic or renal failure. (1987) (1)
Evidnece that human platelet aggregating activity in porcine plasma is a property of von Willbrand factor. (1974) (1)
Aluminium Nicotinate as a Hypocholesterolemic Agent (1965) (1)
Production of human anti-factor VIII monoclonal IgG antibodies by immortalisation of B lymphocytes from haemophilia A patients with inhibitors (1997) (1)
The activation of fibrinolysis with 3-pyridil-acetic acid. (1966) (1)
The antithrombotic effects of calin, a platelet-adhesion inhibitor from the medicinal leech, in a hamster femoral vein platelet-rich mural thrombosis model (1993) (1)
The Serum of Normal Donors Contains Both Anti-factor-viii and Corresponding Antiidiotypic Antibodies (1991) (1)
Pregnancy and thrombosis (2003) (1)
FIBRINOLYTIC ACTIVITY AND OXYGEN DESATURATION OF VENOUS BLOOD (1964) (1)
Anti-factor VIII antibodies belonging to the IgA1 isotype in a mild haemophilia A patient (1998) (1)
An easy method to detect patients with vonwillebrand-factor defective in fviii-binding (1991) (1)
Reorientation of cyclic endoperoxide metabolism and efficacy of thromboxane synthetase inhibitors (tsi) (1983) (1)
Percutaneous transluminal atherectomy: Preliminary results (1990) (1)
THROMBOSIS IN INJURED SMALL VESSELS (1991) (1)
DUAL EFFECT OF FLUORIDE ON ENDOTHELIAL PROSTACYCLIN PRODUCTION (1987) (1)
[Inhibition of platelet aggregation: experimental findings and clinical prospects]. (1971) (1)
Congenital antithrombin III deficiency. A description of two Belgian families. Therapeutic implications. (1982) (1)
A dominant negative mutation in the P2X1 receptor causes a severe bleeding disorder. (1999) (1)
Acute and chronic "defibrination" in obstetrical practice. (1968) (1)
Physical and chemical properties of normal and haemophilic factor VIII. (1975) (1)
Evaluation of three methods of platelet labelling. (1986) (1)
A single mutation Arg2150His regulates T cell specificity for the FVIII C1 domain: a molecular mechanism responsible for the higher incidence of inhibitors in mild/moderate hemophilia A patients with mutations in the C1 domain (2002) (1)
Prostacyclin stimulatory activity of reducing cofactors in human plasma filtrate. A potential role for uric acid (1987) (1)
Clot retraction inhibition test: a simple method to evaluate platelet aggregation (1972) (1)
Exposure of von Willebrand factor to shear forces stimulates A1 domain mediated interaction with collagen (1997) (1)
Platelet aggregation and anaesthesia. (1980) (1)
[Biologic data obtained in the course of various cases of acute defibrination]. (1968) (1)
[Molecular defects of coagulation factors and of the fibrinolytic system associated with thromboembolism]. (1987) (1)
A mechanism for platelet clumping by a specific human IgG immunoglobulin (1970) (1)
Recent progress in thrombolytic therapy. (1969) (1)
Anticoagulant versus no specific treatment in childhood hemolytic uremic syndrome. A randomized prospective study (1981) (1)
PITFALLS IN THE THROMBOLYTIC TREATMENT OF VENOUS OCCLUSION. (1964) (1)
Recovery of endothelial function and coronary plaque stabilisation after lipid lowering in LDL-hypercholesterolaemic pigs (2001) (1)
Effect of heparin on platelets. (1972) (1)
LOW-MOLECULAR-WEIGHT FACTOR VIII (1973) (1)
T cell immune response towards Factor VIII in mild/moderate hemophilia A patients: the carboxy-terminal part of the C1 domain is an important source of T cell epitopes (1999) (1)
[Inhibition of integrin function prevents restenosis following vascular injury]. (1995) (1)
Severe combined immunodeficiency (SCID) mice can be used for the pre-clinical evaluation of factor VIII preparation immunogenicity (1996) (1)
Correlation between initial thrombus size and neointima formation in the damaged hamster carotid-artery (1995) (1)
Recirculated normal platelets adhere to surfaces coated with plasma from patients with immune thrombocytopenia. (1997) (1)
4 Interaction of recombinant tissue-type plasminogen activator (rt-PA) and murine anti-platelet GPIIb/IIIa monoclonal antibody in a canine femoral vein thrombosis model (1988) (1)
The platelet adhesion-aggregation reaction (PAAR) and plasma proteins (1974) (1)
Platelet adhesion to non-damaged aorta endothelium of cholesterol-fed rabbits is mediated by von Willebrand factor (1997) (1)
Changes in fibrinolytic parameters during and after prolonged streptokinase administration (1968) (1)
PLATELET AGGREGATION AND ANÆSTHESIA (1980) (1)
Inhibition of endothelial prostacyclin production by a guanine-nucleotide dependent inhibition of phospholipase-c (1989) (1)
Measurement of vonwillebrand-factor antigen in plasma and platelets with an enzyme-linked-immunosorbent-assay based on 2 murine monoclonal-antibodies (1991) (1)
Enhancing blood fibrinolytic activity by a niacin compound 3. Study of the activation mechanism. (2009) (1)
Diagnosis and treatment of disseminated intravascular coagulation. (1967) (1)
Absence of plasminogen activator inhibitor type I (PAI-1) in a human platelet-derived λgtII expression library (1992) (1)
Inhibitor outbreak associated with the use of Octavi SDPlus: summary of experimental results (1998) (0)
[Methods for the measurement in vitro of spontaneous fibrinolytic activity in the venous blood of humans]. (1961) (0)
von Willebrand factor type 2B-like alterations induced by a monoclonal antibody (1997) (0)
Platelet recruitment in vivo to injured blood vessels is not prevented by GPIIb/IIIa antagonism (2003) (0)
adenylate cyclase activity human platelets by simultaneous modulation of phospholipase C and Sodium fluoride mimics effects of both agonists and antagonists on intact (2011) (0)
No evidence for an inhibition of fibrinolysis in the pathogenesis of childhood hemolytic-uremic syndrome (1995) (0)
[Critical evaluation of thrombolytic therapy with streptokinase in acute arterial occlusion]. (1965) (0)
Blood Disorders in the Elderly: Blood coagulation and aging (2007) (0)
neointima formation Inhibition of integrin function by a cyclic RGD-containing peptide prevents (2011) (0)
the b1-tubulin Q43P functional polymorphism reduces the risk of cardiovascular disease by modulating platelet function and structure (2005) (0)
A Monoclonal-antibody Induces Changes in the Function of Normal Von-willebrand-factor (vwf), That Then Behaves Like Type-iib (1993) (0)
Therapeutic potential for a novel regulatory mechanism of megakaryopoiesis by the PACAP peptide and its receptor VPAC1 (2007) (0)
R68070, a combined thromboxane/endoperoxide receptor antagonist (TRA) and thromboxane synthase inhibitor (TSI), prolongs the bleeding time more than aspirin in man. (1989) (0)
The anti-factor VIII antibody repertoire of healthy blood donors is reconstituted in the SCID mouse model (1998) (0)
antibodies is subtype-dependent Human platelet aggregation by murine monoclonal antiplatelet (2011) (0)
The treatment of chronic arterial occlusions with streptokinase (1970) (0)
Clonal analysis of an humoral response restricted to allogeneic factor VIII in a mild haemophilia A patient (1998) (0)
Lupus anticoagulans (LA): clinical features of 61 cases (1986) (0)
["Fibrin polymerization time (FPT)-test": a rapid simple and sensitive method for determination of fibrinogenemia]. (1972) (0)
DOES THE MEGAKARYOCYTE CYTOSKELETON REGULATE IRROMBOPOIESIS? (1987) (0)
Underglycosylation in carbohydrate deficient glycoprotein syndrome type 1A and type 2A induces different hemostatic complications (1999) (0)
Thrombospondin-1 secures thrombus adherence in vivo by protecting (sub)endothelial VWF from leavage by ADAMTS13 (2005) (0)
Techniques for detection and clinical significance of platelet antibodies. (1973) (0)
Macrophage-neutrophil cross talk during pulmonary exposure to silica particles triggers peripheral platelet activation via elastase (2005) (0)
Differences in mechanisms by which monoclonal murine anti-human platelet antibodies cause aggregation of baboon and human platelets (1993) (0)
Manipulation of Pro- and Antiaggregating Prostaglandins: New Antithrombotic Strategies (1985) (0)
[Kidney and hemostasis. II. Therapeutic approach to various immunological renal diseases with blood platelet aggregation inhibitors]. (1972) (0)
[Current advances in the diagnosis, prevention and treatment of thrombosis]. (1977) (0)
Title Page / Table of Contents / Preface (2003) (0)
Inhibition of the Production of Prostacyclin in Patients With Lupic Inhibitor (1981) (0)
Abstracts of Papers Presented at a One‐Day Scientific Meeting of the British Society for Haematology, London, 14 November 1980 (1981) (0)
A monoclonal antibody inhibiting factor VIII in a chromogenic substrate based assay but not in a clotting assay (1991) (0)
Circulating platelet aggregates in diabetic-retinopathy and in idiopathic retinal vein-thrombosis (1979) (0)
Laser-Assisted Angioplasty: State of the Art and Future Developments (1990) (0)
The aggregation of human platelets by monoclonal-antibodies is subtype-dependent (1991) (0)
FURTHER EXPERIENCE WITH STREPTOKINASE AS THROMBOLYTIC AGENT. (1964) (0)
Release of endothelial PAI-1 prevents fibrinolysis during acute arterial thrombosis in mice (1999) (0)
Increased incidence of thromboembolic complications in cyclosporine-A (CSA) treated cadaveric kidney allograft recipients (1985) (0)
Factors Affecting the Factor X Activator Activity of Human Platelets (1977) (0)
Deletion of residue Ala2201 in the Factor VIII C2 domain impairs FVIII interactions with phospholipids and VWF and results in mild haemophilia A (2003) (0)
The prevalence of Transfusion Transmitted Virus (TTV) infection in Belgian population: an epidemiological study for the clinical significance (2000) (0)
DENTAL MANAGEMENT OF ANTICOAGULATED PATIENTS (1989) (0)
Cigarette smoking increases the release of prostacyclin into the coronary circulation in patients with ischemic heart disease (1982) (0)
Antiplatelet Activity of Suloctidil I.V. Perfusion (1979) (0)
[On thrombolytic therapy]. (1961) (0)
Rapid Ca2+ influx via the platelet P2X1 ion channel requires its N- and C-terminal tyrosine phosphorylation. (2001) (0)
[CURRENT POSSIBILITIES AND COMPLICATIONS OF THROMBOLYTIC TREATMENT]. (1963) (0)
Mutations scattered in the C1 domain destroy T cell epitopes: a molecular mechanism responsible for the higherincidence of inhibitor in mild/moderate haemophilia A patients with mutations in the C1 domain (2001) (0)
Factor VIII inhibitor. (1993) (0)
Role of laminin and fibronectin in surface coverage of subendothelium by platelets following vWF and GPIIb/IIIa blockade in shear flow conditions (1997) (0)
Non-receptor-mediated refractoriness in prostacyclin production by human endothelial cells in a continuous flow system is delayed by a low-molecular-weight plasma fraction devoid of reducing cofactors for peroxidase-catalysed reactions. (1990) (0)
Trombose als uiting van immuunpathologie (1986) (0)
Preliminary results of percutaneous transluminal atherectomy. (1990) (0)
The quality of care in the management of oral anti-coagulation therapy by the Belgian general practitioner (2003) (0)
The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation and megakaryocyte maturation (2003) (0)
Index rerum ad Vol. 13 (1965) (0)
patients treated exclusively with lyophilized cryoprecipitate Incidence of inhibitor development in a group of young hemophilia A (2011) (0)
Impact of LDL-hypercholesterolemia and LDL lowering on atherosclerosis, endothelial reactivity and heart function in miniature pigs (2001) (0)
FORTHCOMING ARTICLES IN THE JANUARY ISSUE (2006) (0)
Antibodies to idiotypes of human monoclonal anti-Factor VIII (FVIII) antibodies neutralise their inhibitory activity (1999) (0)
The Q43P b1tubulin substitution modifies platele function and structure and is a predisposing factor for thrombocytopenia (2005) (0)
Congenital abnormal fibrinogen, type Leuven (1968) (0)
[Effect of acetylsalicylic acid and other anti-inflammatory drugs on platelet aggregation]. (1971) (0)
Digital gangrene due to intimal proliferation without extravascular changes of scleroderma. A diagnostic challenge. (Abstract) (1981) (0)
Aggregation of human platelets by bovine and human factor VIII (F VIII) (1973) (0)
[Angioplasty using a Nd:YAG laser with a sapphire probe]. (1990) (0)
Contents Vol. 32, 2002 (2002) (0)
Platelet aggregation by Thrombofax. (1972) (0)
Drugs ued in bleeding (1993) (0)
Anti-Factor VIII inhibitory antibodies belonging to the IgA1 isotype in a mild hemophilia A patient (1997) (0)
[Constitutional abnormalities of the "prothrombin complex"]. (1967) (0)
Whole-blood prostacyclin production in children with hus (1982) (0)
Shear stress induced platelet aggregation: A mechanosensory role for the ATP-gated P2X(1) ion channel (2003) (0)
FEMORO-POPLITEAL ARTERY THROMBOLYSIS WITH INTRA-ARTERIAL INFUSION OF RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR (rt-PA) (1987) (0)
Drugs affecting blood coagulation, fibrinolysis and hemostasis (2001) (0)
Production of human IgG monoclonal antibodies neutralising the functional activity of factor VIII by immortalisation of B lymphocytes from a haemophilia A patient with inhibitor (1996) (0)
autoantibody directed against platelet glycoprotein Ia/IIa Production and nucleotide sequence of an inhibitory human IgM (2011) (0)
A new patient with congenital functional fibrinogen abnormality (1968) (0)
RISTOMYCIN (AGGRISTIN) PRECIPITATION TEST: A NEW, RAPID AND RELIABLE METHOD FOR THE DETECTION OF INTRAVASCULAR CLOTTING (1987) (0)
Percutaneous transluminal angioplasty: preliminary results. (1981) (0)
Shear stress-induced unfolding of von Willebrand factor triggers ptoent A1 domain binding to fibrillar collagen, supportive of platelet binding to collagen (2003) (0)
Protein-kinase-c dependent modulation of guanine nucleotide-dependent inhibition of phospholipase-c and concomitant phosphorylation of gz in human endothelial-cells (1991) (0)
Trombose als uiting van immuunpathologie deel I (1988) (0)
The P2X1 ion channel in platelets acts as a functional receptor for ATP and is weakly antagonized by ADP. (2001) (0)
Piracetam has an antiplatelet effect invivo and invitro (1991) (0)
Human anti-FVIII alloantibodies are not of restricted isotypic origin (1992) (0)
High levels of IFNgamma production by FVIII-specific T cells from a mild/moderate hemophilia A patient with inhibitor (2000) (0)
Drugs modulating prostacyclin production as potential antithrombotic agents (1982) (0)
Mutations in the Factor VIII C1 domain reducing Factor VIII binding to von Willebrand Factor and resulting in mild/moderate haemophilia A do not prevent a clinically useful response to DDAVP (2001) (0)
Glycosylation of a type 2 Factor VIII inhibitor determines its maximum level of Factor VIII inhibition (2003) (0)
Fourth European Workshop on Inflammation Wilrijk March 1982 (1982) (0)
The inhibition of fibrinolysis by large streptokinase concentrations (1964) (0)
[Thrombolytic therapy with a standardized system of dosage of purified streptokinase]. (1966) (0)
DURATION OF BLEEDING FOLLOWING DENTAL EXTRACTION IN RABBITS:IN FLUENCE OF PLATELET DYSFUNCTION (1987) (0)
A population of anti-factor VIII antibodies produced in vitro by B lymphocytes from haemophilia A patients with inhibitors does not inhibit factor VIII function (1996) (0)
A double blind study of the effect of tranexamic acid in essential menorrhagia. (1968) (0)
Rapid latex-screening test for urine F.D.P. (1973) (0)
A murine monoclonal-antibody contains an rgd-sequence in the heavy-chain cdr3 (h3) involved in the inhibition of platelet glycoprotein-iib/iiia function (1993) (0)
A mouse model for the study of tolerance to Factor VIII (1999) (0)
[Kidney and hemostasis. I. Significance of the fibrinogen-similar material in immunologic renal diseases and in crisis of transplanted kidney rejection]. (1972) (0)
Platelet activation by cross-linking of a platelet membrane-protein associated with actin (1995) (0)
[Blood coagulation problems in the surgical patient]. (1970) (0)
[Prostaglandins, thrombosis and hemorrhage]. (1982) (0)
Outpatient angiography. (1990) (0)
A pilot study on thrombolysis with recombinant staphylokinase (star) in patients with peripheral arterial occlusion (1994) (0)
Furosemide, Fibrinolytic Activity and Urokinase Excretion (1977) (0)
[Determination of fibrinogen-like material in biological fluids]. (1970) (0)
Humanized monoclonal anti-CD40 Ligand (CD154) antibody (Hu5c8) treatment inhibits the production of anti-factor VIII antibodies by SCID mice reconstituted with PBMC of a severe hemophilia patient with inhibitor (2000) (0)
Role of pulmonary inflammation on the peripheral thrombotic risk following intratracheal instillation of diesel exhaust particles (2003) (0)
Enhanced Platelet Reactivity to Collagen and Shear Stress in Transgenic Mice Overexpressing the Platelet P2X1 Ion Channel (2002) (0)
Ergotisme: van epidemie tot latrogene verwikkeling (1974) (0)
Acquisitions Recentes Dans Le Diagnostic, La Prevention Et Le Traitement Des Thromboses (1977) (0)
Molecular characterisation of a factor VIII specific IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor (1997) (0)
[The administration of streptokinase therapy]. (1965) (0)
In vivo and in vitro effect of brinase on plasma fibrinogen: a gel filtration study (1973) (0)
FURTHER EXPERIENCE WITH STREPTOKINASE AS THROMBOLYTIC AGENT. (1964) (0)
Problems in the detection of hemophilia carriers (1966) (0)
Subject Index, Vol. 17, 1987 (1987) (0)
Factor VIII Inhibition of Human Platelet Aggregation by Plasmin Digests of Human (2012) (0)
22. Miscellanea22.8 Quality Assessment of Oral Anticoagulation in Patients with AF (2005) (0)
Letter: Platelet adhesion and clot retraction. (1973) (0)
Is thrombolytic treatment effective in acute myocardial infarction (1972) (0)
The Gs agonist PACAP(1-38) is a physiological inhibitor of platelet aggregation and megakaryocyte maturation (2003) (0)
Fatal complication of desmopressin. (1995) (0)
[Changes in the area of the chemical parameters during streptokinase infusion]. (1969) (0)
[Indications for thrombolytic treatment]. (1961) (0)
Drugs affecting blood coagulation and fibrinolysis (1994) (0)
Clonal analysis of the humoral and cellular immune responses towards factor VIII in mild/moderate hemophilia A patients: the carboxy-terminal part of the C1 domain is an important source of antigenic determinants (2000) (0)
A human monoclonal antibody from a mild h emophilia A patient neutralising allogeneic but not autologous factor VIII (1997) (0)
Studies with an imidazole derivative as apossible antithrombotic agent (1980) (0)
Single-blind, randomized study comparing heparin and streptokinase therapy in recent myocardial infarction (1968) (0)
Belgian standards for factor VIII related properties: preliminary data. (1982) (0)
Contents, Vol. 13, 1965 (1965) (0)
Complement Dependent and Independent Effects of Bacterial Products on Rabbit and Human Platelets (1977) (0)
Current indications and accomplishments with thrombolytic therapy (1976) (0)
Schmidt,a memorial lecture - peroxides in hemostasis and thrombosis (1985) (0)
Bm-13.177 specifically blocks the platelet thromboxane receptor (1984) (0)
On the Combined Administration of Streptokinase and Pancreatic Trypsin Inhibitor (1964) (0)
A T cell epitope in the C1 domain is presented by a MHC class II haplotype DRB1*1501/DRB5*01 frequently associated to development of Factor VIII inhibitor antibody (2001) (0)
The multiple faces of the partial thromboplastin time APTT (2004) (0)
Von-willebrand-factor binding to endothelial-cell extracellular-matrix collagen type-vi (1995) (0)
De preventie, diagnose en behandeling van trombose (1985) (0)
Plasma 6-keto-PGF1 alpha levels after plasma exchange in thrombotic thrombocytopenic purpura. (1980) (0)
Pharmacological modification of urinary excretion of fibrinogen-like material in glomerulonephritis. (2009) (0)
Increased platelet reactivity to collagen in transgenic mice overexpressing the P2X1 ion channel. (2002) (0)
Abstract (2003) (0)
In vitro and in vivo recovery of cryoprecipitated factor 8. (1970) (0)
Problems in the detection of hemophilia carriers. Principles of a factor 8 assay on capillary blood. (1966) (0)
Platelet aggregation by Thrombofax®. Studies on the mechanism of action (1973) (0)
Platelet aggregation and clot retraction by two preparations of staphylocoagulase. (1974) (0)
Mutation Arg2150His decreases FVIII binding to vWF but does not prevent a clinically effective response to DDAVP (1999) (0)
The labyrinth of bleeding disorders. An algorithm based on five tests. (1986) (0)
Characterisation of a human monoclonal IgG4 antibody inactivating factor VIII following a type II inhibition pattern and derived from a mild haemophilia A patient with inhibitor (1998) (0)
[Thrombolytic substances and pharmacological agents used for fibrinolytic activity in the blood stream in increased coagulation time]. (1961) (0)
FVIII pasteurisation alters light chain immunoreactivity (1999) (0)
Reduced Production Of 6-Ket0-PGF1α By Umbilical Artery In Pre-Eclampsia (1981) (0)
Domain A1 in unfolded von Willebrand factor can recruit flowing platelets to collagen surfaces independently of domain A3 (2005) (0)
Ca2+ influx via the platelet P2X1 ion channel contributes to collagen-induced platelet activation. (2002) (0)
P2X1-mediated activation of Ca2+-calmodulin leads to myosin light chain and ERK2 phosphorylation in human platelets. (2002) (0)
A specific human immunoglobulin G preparation causing platelet clumping through a release reaction. (2009) (0)
DISSOCIATION OF PHOSPHOLIPASE A2 ACTIVATION FROM CYTOSOLIC FREE CA2+ MOBILIZATION IN PLATELETS EXPOSED TO FLUORIDE (1987) (0)
PLATELET MEMBRANE GLYCOPROTEINS ABNORMALITIES IN PATIENTS WITH ACUTE LEUKEMIAS AND MALIGNANT LYMPHOMAS (1987) (0)
Trombose als uiting van immuunpathologie deel II (1988) (0)
Contents, Vol. 10, 1981 (1981) (0)
[High circulating prostacyclin levels in patients with chronic renal insufficiency (author's transl)]. (1981) (0)
[Significance of fibrinuria for the evolution of treated glomerulonephritis]. (1975) (0)
Shielding the Front A1 Domain Pocket of von Willebrand Factor Inhibits Its Binding to Platelet Glycoprotein Iba (2003) (0)
The Arg2150His mutation within the Factor VIII C1 domain eliminates a B cell epitope that is present only on Factor VIII-von Willebrand factor complexes (1998) (0)

This paper list is powered by the following services:

Jozef Vermylen's Academic­Influence.com Rankings

Why Is Jozef Vermylen Influential?

Jozef Vermylen's Published Works

Published Works

Jozef Vermylen's AcademicInfluence.com Rankings